Skip to main content
. 2007 May;121(1):140–145. doi: 10.1111/j.1365-2567.2006.02553.x

Figure 1.

Figure 1

RC-101 inhibits HIV-1 infection of vaginal tissues. (a) Vaginal tissues were treated with either HIV-1 BaL alone or with HIV-1 BaL in the presence of RC-101 (2 μg in 100 μl PBS) and then maintained for 9 days as described in the Materials and methods. Tissue DNA (200 ng) served as templates for real-time polymerase chain reaction using primers specific for HIV-1 BaL 5′ LTR, gag, or env, or for cellular β-actin (control). Results are presented as fold-decrease in HIV-1 BaL DNA for RC-101 versus vehicle-treated vaginal tissues (mean ± SEM, n = 3). (b–d) Quantitative analysis of HIV-1 reverse transcripts in RC-101 versus vehicle-treated vaginal tissues. Standard curves for HIV-1 transcript and β-globin levels were generated by plotting cycle threshold (Ct) values for known numbers of input templates (b), and Ct values for tissue DNA samples were fit to the standard curves and presented as copies of HIV-1 transcript per 10 000 copies of β-globin. (c) Vaginal tissues were treated with either 2 μg or 0·2 μg RC-101 at the time of HIV-1 BaL infection and then maintained for 9 days as described in the Materials and methods. (d) Levels of HIV-1 transcript in full-thickness tissues treated with HIV-1 BaL alone or in the presence of 2 μg RC-101. Bars represent mean ± SEM, n = 4. *P < 0·01.